Article
Identification of multiple serine to asparagine sequence variation sites in an intended copy product of LUCENTIS® by mass spectrometry.
mAbs - 1 Jan 2000
Griaud François, Winter Andrej, Denefeld Blandine, Lang Manuel, Hensinger Héloïse, Straube Frank, Sackewitz Mirko, Berg Matthias
Abstract excerpt
Patent expiration of first-generation biologics and the high cost of innovative biologics are 2 drivers for the development of biosimilar products. There are, however, technical challenges to the production of exact copies of such large molecules. In this study, we performed a head-to-head comparison between the originator anti-VEGF-A Fab product LUCENTIS® (ranibizumab) and an intended copy product using an...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.